Impact News +++ Better Home & Finance Holding Company to Announce Fourth Quarter and Full Year 2025 Results (Business Wire) +++ BETTER HOME Aktie +3,09%

STEREOTAXIS Aktie

>STEREOTAXIS Aktienkurs

1.86 EUR +1.1% (TradegateBSX)

Ask: 1.98 EUR / 900 Stück

Bid: 1.83 EUR / 1000 Stück

Tagesumsatz: 6 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

STEREOTAXIS Aktie über LYNX handeln

Intraday

1 Jahr

>STEREOTAXIS Performance

1 Woche: +3,3%

1 Monat: -1,1%

3 Monate: -5,6%

6 Monate: -21,8%

1 Jahr: -7,9%

laufendes Jahr: -5,1%

>STEREOTAXIS Aktie

Name:

STEREOTAXIS DL-,01

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US85916J4094 / A1J09L

Symbol/ Ticker:

RJR1 (Frankfurt)

Kürzel:

FRA:RJR1, ETR:RJR1, RJR1:GR

Index:

Webseite:

http://www.stereotaxis.co..

Profil:

Stereotaxis Inc. is a cutting-edge medical technology company that specializes in robotic systems for minimally invasive surgery. The company's primary focus is on the development and commercializatio..
>Volltext..

Marktkapitalisierung:

170.63 Mio. EUR

Unternehmenswert:

170.92 Mio. EUR

Umsatz:

25.46 Mio. EUR

EBITDA:

-17.96 Mio. EUR

Nettogewinn:

-20 Mio. EUR

Gewinn je Aktie:

-0.24 EUR

Schulden:

4.73 Mio. EUR

Liquide Mittel:

8.89 Mio. EUR

Operativer Cashflow:

-7.15 Mio. EUR

Bargeldquote:

0.52

Umsatzwachstum:

13.49%

Gewinnwachstum:

-3.93%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

STEREOTAXIS

Letzte Datenerhebung:

03.03.26

>STEREOTAXIS Kennzahlen

Aktien/ Unternehmen:

Aktien: 93.32 Mio. St.

Frei handelbar: 83.04%

Leerverk. Aktien: -

Rückkaufquote: -3.95%

Mitarbeiter: 139

Umsatz/Mitarb.: 0.16 Mio. EUR

Analysten:

Analystenrating: Strong buy

Kursziel: 88.11%

Bewertung:

KGV: -

KGV lG: -

KUV: 6.78

KBV: 32.41

PEG-Ratio: -2.31

EV/EBITDA: -

Rentabilität:

Bruttomarge: 53.07%

Gewinnmarge: -78.56%

Operative Marge: -75.61%

Managementeffizenz:

Gesamtkaprendite: -48.96%

Eigenkaprendite: -170.24%

>STEREOTAXIS Peer Group

Gesundheit, Medizinprodukte & -technik/ Implantate/ Wundpflege

>STEREOTAXIS Chart & Kurs - Tradegate

>STEREOTAXIS News

12.02.26 - 15:03

Stereotaxis to Report Fourth Quarter and Full Year 2025 Financial Results on March 9, 2026 (GlobeNewswire EN)

ST. LOUIS, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2025 fourth quarter and full year on Monday, March 9, 2026 at the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. ET that day to discuss the Company's results and corporate developments....

09.02.26 - 14:09	Klinikum Fürth Establishes Leading Robotic Heart Arrhythmia Program (GlobeNewswire EN)
	ST. LOUIS, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the launch of a new robotic electrophysiology program at Klinikum Fürth in Fürth, Germany....

06.01.26 - 18:30	Stereotaxis: Aktie legt nach FDA-Zulassung für Roboter-Katheter kräftig zu (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

06.01.26 - 14:06	Stereotaxis Receives FDA Approval for MAGiC Ablation Catheter (GlobeNewswire EN)
	ST. LOUIS, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced it obtained U.S. Food and Drug Administration (FDA) approval for the MAGiC™ Magnetic Interventional Ablation Catheter....

24.11.25 - 15:00	Stereotaxis to Participate in Piper Sandler 37th Annual Healthcare Conference (GlobeNewswire EN)
	ST. LOUIS, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that the company will participate in the Piper Sandler 37th Annual Healthcare Conference....

13.11.25 - 21:15	STXS Secures FDA Approval for GenesisX to Broaden Surgical Robotics (Zacks)
	Stereotaxis wins FDA clearance for GenesisX, a streamlined robotic system aimed at boosting hospital adoption and accelerating growth....

12.11.25 - 11:06	Stereotaxis shares drop after Q3 loss widens, GenesisX limited launch underway (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

12.11.25 - 01:00	Stereotaxis Inc. (STXS) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
	Stereotaxis (STXS) delivered earnings and revenue surprises of +50.00% and -13.21%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?...

11.11.25 - 23:54	Stereotaxis verfehlt Umsatzprognose für Q3 2025 – Aktie legt dennoch zu (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

11.11.25 - 22:06	Stereotaxis GAAP EPS of -$0.07 misses by $0.01, revenue of $7.46M misses by $0.92M (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

11.11.25 - 22:03	Stereotaxis Reports 2025 Third Quarter Financial Results (GlobeNewswire EN)
	ST. LOUIS, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the third quarter ended September 30, 2025....

10.11.25 - 23:36	Stereotaxis Q3 2025 Earnings Preview (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

21.10.25 - 15:03

Stereotaxis to Report Third Quarter 2025 Financial Results on November 11, 2025 (GlobeNewswire EN)

ST. LOUIS, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2025 third quarter on Tuesday, November 11, 2025 at the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. ET that day to discuss the Company's results and corporate developments....

20.10.25 - 16:45	Stereotaxis Rolls Out Synchrony System in EU and Files for FDA Approval (Zacks)
	STXS expands its digital surgery vision with the EU launch of its Synchrony System and an FDA submission for market entry....

15.10.25 - 13:33	Stereotaxis Announces EU Launch and 510(k) Submission for Synchrony System to Modernize Interventional Cath Labs (GlobeNewswire EN)
	ST. LOUIS, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced it obtained CE Mark in Europe and submitted a 510(k) application to the FDA in the US for the Synchrony™ system....

14.10.25 - 20:30	STXS Partners With CardioFocus to Boost Robotic Pulsed Field Ablation (Zacks)
	Stereotaxis partners with CardioFocus to commercialize the first robotic Pulsed Field Ablation system, aiming to revolutionize cardiac arrhythmia treatment....

13.10.25 - 13:36

Stereotaxis & CardioFocus Collaborate to Advance Robotic Pulsed Field Ablation for Cardiac Arrhythmias (GlobeNewswire EN)

ST. LOUIS and MARLBOROUGH, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, and CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for cardiac arrhythmias, today announced they have entered into a Collaboration Agreement to advance robotic Pulsed Field Ablation (PFA) technology towards commercialization....

23.09.25 - 20:30	STXS Stock Gains as Erasmus Medical Adopts Its Genesis Robotic System (Zacks)
	Stereotaxis stock gains as Erasmus Medical adopts Genesis robotic system, marking a milestone in cardiac arrhythmia care....

22.09.25 - 16:54	New Robotic System Promises Faster, Safer Care For Arrhythmia Patients (Benzinga)
	Stereotaxis (AMEX: STXS) announces first procedures with Genesis Robotic Magnetic Navigation System for minimally invasive endovascular interventions. read more...

22.09.25 - 13:57	Erasmus Medical Center Advances Cardiovascular Care with Genesis Robotic System (GlobeNewswire EN)
	ST. LOUIS, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced successful first procedures by physicians at Erasmus University Medical Center in Rotterdam, The Netherlands, using the advanced Genesis Robotic Magnetic Navigation System....

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Das Übel nährt sich nur von seinesgleichen. Weise Menschen vergalten daher nicht Böses mit Bösem, sondern immer nur mit Gutem und brachten dadurch das Böse zu Fall. - Mohandas

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram